Human growth hormone (HGH) has been used clinically since the 1950s. It entered the longevity space when research demonstrated its effects on body composition, recovery, and aging biomarkers. The problem is that exogenous HGH comes with significant limitations that growth hormone secretagogues largely avoid.
The Problems with Exogenous HGH
Exogenous HGH bypasses the pituitary entirely — suppressing your body's own GH production through negative feedback. It produces supraphysiologic, non-pulsatile GH levels that don't replicate natural GH patterns. At higher doses, HGH increases risk of insulin resistance, carpal tunnel syndrome, and joint swelling. Cost runs $500–1,500 per month for quality pharmaceutical product.
How Sermorelin Is Different
Sermorelin is a synthetic analog of GHRH — growth hormone-releasing hormone. Rather than delivering GH directly, it stimulates the pituitary to produce and release its own GH in the natural pulsatile pattern. The pituitary's response is subject to negative feedback regulation — if GH is already adequate, the pituitary blunts its response. This built-in regulation prevents supraphysiologic levels. Sermorelin does not suppress endogenous production. Cost is $100–300 per month.
The Evidence Base
A review by Walker et al. in Clinical Interventions in Aging found that sermorelin therapy in GH-deficient adults improved body composition, sleep quality, energy, and cognitive function. Studies document 26% increases in IGF-1 levels with sermorelin — a meaningful improvement in a key growth hormone biomarker.
Who Should Use Which
Sermorelin is the first-line approach for most adults interested in GH optimization for longevity, body composition, recovery, and sleep. Exogenous HGH is appropriate for documented adult GH deficiency where the pituitary cannot produce adequate GH even when stimulated.